Compare · ENOV vs EW
ENOV vs EW
Side-by-side comparison of Enovis Corporation (ENOV) and Edwards Lifesciences Corporation (EW): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ENOV and EW operate in Industrial Specialties (Health Care), so they compete in similar markets.
- EW is the larger of the two at $50.04B, about 47.6x ENOV ($1.05B).
- Over the past year, ENOV is down 41.6% and EW is up 16.3% - EW leads by 57.9 points.
- ENOV has been more active in the news (8 items in the past 4 weeks vs 7 for EW).
- EW has more recent analyst coverage (25 ratings vs 20 for ENOV).
- Company
- Enovis Corporation
- Edwards Lifesciences Corporation
- Price
- $18.23-0.79%
- $86.80-2.25%
- Market cap
- $1.05B
- $50.04B
- 1M return
- -27.70%
- -4.13%
- 1Y return
- -41.63%
- +16.26%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 8
- 7
- Recent ratings
- 20
- 25
Enovis Corporation
Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. Enovis Corporation sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. The company was formerly known as Colfax Corporation. Enovis Corporation is headquartered in Wilmington, Delaware.
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Latest ENOV
- Enovis becomes first multi-registry industry sponsor of AAOS Registry Program
- Chief Administrative Officer Engert Oliver bought $50,008 worth of shares (2,660 units at $18.80), increasing direct ownership by 4% to 63,898 units (SEC Form 4)
- Chief Executive Officer Mcdonald Damien bought $249,620 worth of shares (13,035 units at $19.15), increasing direct ownership by 6% to 247,077 units (SEC Form 4)
- Chief Administrative Officer Engert Oliver bought $149,971 worth of shares (7,598 units at $19.74), increasing direct ownership by 14% to 61,238 units (SEC Form 4)
- eCential Robotics Announces Binding Offer from Enovis
- Enovis Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Enovis Invests in Innovation with Binding Offer to Acquire eCential Robotics, a Leading Developer of Enabling Technologies and Surgical Robotics
- Enovis to Participate in the 2026 Wells Fargo Healthcare Conference
- SEC Form 10-Q filed by Enovis Corporation
- Enovis Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest EW
- SVP, Corporate Controller Dahl Andrew M. covered exercise/tax liability with 253 shares, decreasing direct ownership by 2% to 14,615 units (SEC Form 4) to satisfy withholding tax
- CVP, JAPAC Markowitz Wayne covered exercise/tax liability with 923 shares, decreasing direct ownership by 5% to 19,371 units (SEC Form 4) to satisfy tax liability
- CVP, TAVR Lippis Daniel J. exercised 619 shares at a strike of $72.68 and sold $54,169 worth of shares (619 units at $87.51) as part of a pre-agreed trading plan (SEC Form 4)
- CVP, TMTT, Surgical & IHFM Chopra Daveen covered exercise/tax liability with 398 shares, decreasing direct ownership by 0.90% to 43,926 units (SEC Form 4) to satisfy tax liability
- Edwards Lifesciences Comments on TAVR National Coverage Decision
- Edwards Lifesciences to Present at the Deutsche Bank Healthcare Summit
- SVP, Corporate Controller Dahl Andrew M. sold $49,534 worth of shares (544 units at $91.06), decreasing direct ownership by 4% to 14,868 units (SEC Form 4)
- CVP, EMEACLA Bruls Annette sold $237,907 worth of shares (2,644 units at $89.98), decreasing direct ownership by 13% to 17,984 units (SEC Form 4)
- Edwards Lifesciences Corporation filed SEC Form 8-K: Leadership Update
- CVP, TMTT, Surgical & IHFM Chopra Daveen exercised 31,800 shares at a strike of $72.68 and sold $2,894,440 worth of shares (31,800 units at $91.02) (SEC Form 4)